SageView Advisory Group LLC Purchases New Stake in Boston Scientific Co. (NYSE:BSX)

SageView Advisory Group LLC acquired a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 9,578 shares of the medical equipment provider’s stock, valued at approximately $588,000.

Several other large investors also recently made changes to their positions in the business. Bruce G. Allen Investments LLC acquired a new position in shares of Boston Scientific during the 4th quarter valued at $28,000. Sachetta LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth about $32,000. Frazier Financial Advisors LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth about $32,000. Motco boosted its position in shares of Boston Scientific by 136.3% in the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 372 shares during the period. Finally, Venturi Wealth Management LLC grew its stake in shares of Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 215 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $75.63 on Monday. The company has a market cap of $110.96 billion, a PE ratio of 63.55, a P/E/G ratio of 2.60 and a beta of 0.77. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $76.25. The company has a fifty day moving average price of $70.61 and a two-hundred day moving average price of $63.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating the consensus estimate of $0.51 by $0.05. The business had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. Research analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on BSX. Needham & Company LLC boosted their price target on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Argus boosted their target price on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Deutsche Bank Aktiengesellschaft raised their price target on shares of Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, April 25th. TD Cowen boosted their price objective on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a report on Thursday, March 7th. Finally, Wells Fargo & Company raised their target price on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Two equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.41.

Insider Activity

In related news, EVP Eric Francis Yves Thepaut sold 12,931 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $74.14, for a total value of $958,704.34. Following the sale, the executive vice president now owns 31,422 shares of the company’s stock, valued at approximately $2,329,627.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $66.35, for a total value of $463,322.05. Following the sale, the executive vice president now directly owns 53,788 shares in the company, valued at approximately $3,568,833.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Eric Francis Yves Thepaut sold 12,931 shares of Boston Scientific stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $74.14, for a total value of $958,704.34. Following the sale, the executive vice president now directly owns 31,422 shares in the company, valued at approximately $2,329,627.08. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,616 shares of company stock valued at $4,819,057. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.